GlassScriptPhysician profile
Rebecca Matro
NPI 1043484405
$153,563.77
in general payments reported to CMS, 2019-2025
21 companies · $47K in 2025
The $47K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,016 · 2020: $294 · 2021: $1,124 · 2022: $17K · 2023: $21K · 2024: $62K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $101K · Consulting Fee: $15K · Travel and Lodging: $7,792 · Food and Beverage: $6,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $101,117.36 |
| Consulting Fee | $14,595.00 |
| Travel and Lodging | $7,792.37 |
| Food and Beverage | $6,445.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $86,931.18 | 2021-2025 | Tremfya, Stelara |
| Abbvie INC. | $57,962.94 | 2020-2025 | |
| Pfizer INC. | $5,032.48 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $631.30 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $541.92 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $527.55 | 2021-2025 | Xifaxan, Trulance |
| Janssen Scientific Affairs, LLC | $441.19 | 2020-2025 | Stelara, Tremfya |
| Regeneron Healthcare Solutions, INC. | $277.96 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $264.26 | 2023-2024 | Dificid, Zinplava |
| Genzyme Corporation | $260.58 | 2022-2025 | |
| Lilly USA, LLC | $128.99 | 2022-2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $101.75 | 2023-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $87.17 | 2021 | |
| Ardelyx, INC. | $75.39 | 2023-2024 | Ibsrela |
| Qol Medical, LLC | $66.70 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $61.95 | 2022-2023 | Sutab |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.18 | 2021-2023 | Cyltezo |
| Redhill Biopharma INC. | $54.88 | 2023-2024 | Talicia |
| Ferring Pharmaceuticals INC. | $26.79 | 2022-2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $16.01 | 2022 | |
| Phadia US INC. | $14.60 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Matro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.